MXPA01009470A - Tratamiento de ciertos canceres asociados con el aumento de peso. - Google Patents

Tratamiento de ciertos canceres asociados con el aumento de peso.

Info

Publication number
MXPA01009470A
MXPA01009470A MXPA01009470A MXPA01009470A MXPA01009470A MX PA01009470 A MXPA01009470 A MX PA01009470A MX PA01009470 A MXPA01009470 A MX PA01009470A MX PA01009470 A MXPA01009470 A MX PA01009470A MX PA01009470 A MXPA01009470 A MX PA01009470A
Authority
MX
Mexico
Prior art keywords
cancers associated
treatment
weight gain
certain cancers
cancer
Prior art date
Application number
MXPA01009470A
Other languages
English (en)
Inventor
Carl M Mendel
Original Assignee
Knoll Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Knoll Gmbh filed Critical Knoll Gmbh
Publication of MXPA01009470A publication Critical patent/MXPA01009470A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se usa un compuesto de la formula (I): (ver formula) o una sal farmaceuticamente aceptable del mismo, donde R1, y R2 son independientemente H o metilo (por ejemplo, clorhidrato de N,N-dimetiI-1-[1-(4-clorofeniI) ciclobutil]-3-metiIbutiIamina, opcionalmente en l a forma de su monohidrato), para tratar canceres asociados con la obesidad, que incluyen cancer de colon, cancer de mama, cancer endometrial y cancer de vesicula biliar.
MXPA01009470A 1999-03-19 2000-03-17 Tratamiento de ciertos canceres asociados con el aumento de peso. MXPA01009470A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12525099P 1999-03-19 1999-03-19
PCT/US2000/007361 WO2000056323A1 (en) 1999-03-19 2000-03-17 Treatment of certain cancers associated with weight gain

Publications (1)

Publication Number Publication Date
MXPA01009470A true MXPA01009470A (es) 2004-03-19

Family

ID=22418838

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA01009470A MXPA01009470A (es) 1999-03-19 2000-03-17 Tratamiento de ciertos canceres asociados con el aumento de peso.

Country Status (19)

Country Link
EP (1) EP1171106A1 (es)
JP (1) JP2002539255A (es)
KR (1) KR20010113765A (es)
CN (1) CN1399545A (es)
AU (1) AU3632000A (es)
BG (1) BG105998A (es)
BR (1) BR0009161A (es)
CA (1) CA2367045A1 (es)
CZ (1) CZ20013281A3 (es)
HU (1) HUP0200497A2 (es)
IL (1) IL145239A0 (es)
MX (1) MXPA01009470A (es)
NO (1) NO20014478L (es)
NZ (1) NZ514012A (es)
PL (1) PL351958A1 (es)
SK (1) SK13372001A3 (es)
TR (1) TR200102692T2 (es)
WO (1) WO2000056323A1 (es)
ZA (1) ZA200107687B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1622600A1 (en) * 2003-04-28 2006-02-08 Cipla Ltd. Pharmaceutical formulation comprising anti-obesity agent and acidulant

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8531071D0 (en) * 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound
US5459164A (en) * 1994-02-03 1995-10-17 Boots Pharmaceuticals, Inc. Medical treatment

Also Published As

Publication number Publication date
SK13372001A3 (sk) 2002-07-02
JP2002539255A (ja) 2002-11-19
CZ20013281A3 (cs) 2002-07-17
BG105998A (en) 2002-06-28
CA2367045A1 (en) 2000-09-28
NO20014478D0 (no) 2001-09-14
TR200102692T2 (tr) 2002-03-21
EP1171106A1 (en) 2002-01-16
PL351958A1 (en) 2003-07-14
IL145239A0 (en) 2002-06-30
NO20014478L (no) 2001-10-29
KR20010113765A (ko) 2001-12-28
BR0009161A (pt) 2002-01-22
HUP0200497A2 (en) 2002-08-28
ZA200107687B (en) 2002-12-18
AU3632000A (en) 2000-10-09
WO2000056323A1 (en) 2000-09-28
NZ514012A (en) 2001-09-28
CN1399545A (zh) 2003-02-26

Similar Documents

Publication Publication Date Title
MY135477A (en) 2-(2,6-dichlorophenyl)-diarylimidazoles
MXPA01009404A (es) Metodo para tratar trastornos de alimentacion.
PH12013500123A1 (en) Hemiasterlin derivatives and uses thereof
PL1653947T3 (pl) Pochodne oksymów (4-hydroksyfenylo)-1H-indolo-3-karbaldehydów jako środki estrogenne
MXPA05009668A (es) Proceso libre de azida para preparar compuestos de 1,2-diamino.
IL177626A0 (en) Pharmaceutical compositions for treating sleep apnoea
DE69907419D1 (en) Antitumorwirkstoffe
TW200508199A (en) Novel compound
WO2000056315A8 (en) Treatment of pain
AU2002364953A8 (en) Topoisomerase poison agents
MXPA01009470A (es) Tratamiento de ciertos canceres asociados con el aumento de peso.
TW200510370A (en) Urea derivatives
MXPA01009461A (es) Tratamiento de osteoartritis.
MXPA01009469A (es) Tratamiento para disminuir la adhesividad de las plaquetas.
MXPA01009468A (es) Tratamiento de hipertension pulmonar.
MXPA01009462A (es) Tratamiento de calculos biliares.
MXPA01009463A (es) Tratamiento de hernia hiatial.
MXPA01009465A (es) Perdida de peso despues del embarazo.
AU2002359762A1 (en) Luminacin analogs and uses thereof